Amarin reported $-16755000 in EBIT for its fiscal quarter ending in March of 2025.


Ebit Change Date
AbbVie USD 5.72B 69M Jun/2025
Alnylam Pharmaceuticals USD 4.89M 13.19M Jun/2025
Amarin USD -16755000 707K Mar/2025
AstraZeneca USD 3.51B 1.3B Jun/2025
DBV Technologies USD -41110000 17.34M Jun/2025
GlaxoSmithKline GBP 2.07B 462M Jun/2025
Halozyme Therapeutics USD 202.44M 54.09M Jun/2025
Ionis Pharmaceuticals USD 144.78M 290.78M Jun/2025
Neurocrine Biosciences USD 145.6M 121.9M Jun/2025
Novartis USD -9190000000 13.87B Jun/2025